 |
| FAP |
The treatment was evaluated in the Fx-006 trial, an open-label extension of the pivotal phase II/III Fx-005 study, which aimed to gauge the long-term safety and efficacy of the drug.
It was found that patients treated with the Pfizer compound for 30 months experienced reduced levels of neurologic deterioration compared to those who began on placebo and switched to tafamidis after 18 months.
The study also showed that those who were switched to tafamidis after 18 months saw their disease progression slowing down after this point.
It is hoped that the drug can prove to be a valuable new treatment for the rare and fatal neurodegenerative disease, for which only limited therapy options currently exist.
Earlier this month, Pfizer agreed a new collaboration with Zacharon Pharmaceuticals that will see the companies working to develop new treatments for rare or orphan diseases.
Sources: http://www.zenopa.com
